A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction – insights from the <scp>ESC‐HFA EORP</scp> Heart Failure Long‐Term Registry
Agnieszka Kapłon‐Cieślicka(Medical University of Warsaw), Lars H. Lund(Karolinska University Hospital), María G. Crespo‐Leiro(Complexo Hospitalario Universitario A Coruña), Gerasimos Filippatos(National and Kapodistrian University of Athens), Theresa A. McDonagh, Lina Benson(Karolinska Institutet), Jarosław Dróżdż(Copenhagen University Hospital), Andrew J.S. Coats(The Heart Research Institute), Mitja Lainščak, Ovidiu Chioncel(Carol Davila University of Medicine and Pharmacy), Giuseppe Rosano(St George's Hospital), Petar Seferović, Alexandre Mebazaa(Marqueurs cardiovasculaires en situation de stress), Camilla Hage(Karolinska Institutet), Massimo Piepoli(University of Milan), Aldo P. Maggioni(Health Care Foundation), Roberto Ferrari(University of Ferrara), Frank Ruschitzka(Kantonsspital St. Gallen), Stefan D. Anker(Charité - Universitätsmedizin Berlin), Gianluigi Savarese(Karolinska Institutet)
Cited by 127
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
2016 European Guidelines on cardiovascular disease prevention in clinical practice
|European Heart Journal|2016|6.5k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k